BidaskClub lowered shares of Agenus (NASDAQ:AGEN) from a sell rating to a strong sell rating in a research note issued to investors on Wednesday, January 3rd.
Other research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Agenus from a hold rating to a buy rating and set a $4.25 price objective on the stock in a research note on Wednesday, October 25th. ValuEngine raised Agenus from a strong sell rating to a sell rating in a research report on Thursday, September 7th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $5.81.
Agenus (NASDAQ AGEN) opened at $3.97 on Wednesday. Agenus has a fifty-two week low of $3.20 and a fifty-two week high of $5.45. The company has a debt-to-equity ratio of -2.39, a current ratio of 1.55 and a quick ratio of 1.55.
Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.37) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.37). The company had revenue of $3.40 million for the quarter, compared to analyst estimates of $5.91 million. The business’s revenue was down 24.4% compared to the same quarter last year. analysts anticipate that Agenus will post -1.16 EPS for the current year.
In other news, CEO Garo H. Armen acquired 100,000 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was purchased at an average cost of $3.55 per share, with a total value of $355,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Karen Valentine sold 8,358 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $3.46, for a total value of $28,918.68. Following the completion of the sale, the insider now directly owns 109,879 shares of the company’s stock, valued at $380,181.34. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 20,514 shares of company stock worth $70,978. Corporate insiders own 7.60% of the company’s stock.
A number of institutional investors have recently made changes to their positions in AGEN. TIAA CREF Investment Management LLC grew its holdings in shares of Agenus by 0.6% during the second quarter. TIAA CREF Investment Management LLC now owns 204,576 shares of the biotechnology company’s stock valued at $800,000 after purchasing an additional 1,283 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Agenus by 6.7% during the second quarter. The Manufacturers Life Insurance Company now owns 63,595 shares of the biotechnology company’s stock valued at $248,000 after purchasing an additional 4,006 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of Agenus by 18.5% during the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 6,381 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of Agenus by 9.7% during the second quarter. Teachers Advisors LLC now owns 141,776 shares of the biotechnology company’s stock valued at $554,000 after purchasing an additional 12,509 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Agenus by 6.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 282,015 shares of the biotechnology company’s stock valued at $1,244,000 after purchasing an additional 16,470 shares during the last quarter. 37.87% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Agenus (AGEN) Downgraded by BidaskClub” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/20/agenus-agen-rating-lowered-to-strong-sell-at-bidaskclub.html.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.